Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150


Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.

Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB.

Am J Hypertens. 1998 Apr;11(4 Pt 1):387-96.


[Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients].

Tasić IS, Mijalković D, Djordjević D, Lović B, Janković D, Miladinović-Tasić N, Lović M.

Srp Arh Celok Lek. 2006 Mar-Apr;134(3-4):106-13. Serbian.


The HOPE Study (Heart Outcomes Prevention Evaluation).

Sleight P.

J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.


Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.

Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S; HOPE Investigators.

Circulation. 2004 Sep 14;110(11):1413-7. Epub 2004 Sep 7.


Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators.

Circulation. 2001 Oct 2;104(14):1615-21.


An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.


Effect of ramipril on left ventricular mass in normotensive hemodialysis patients.

Yu WC, Lin YP, Lin IF, Chuang SY, Chen CH.

Am J Kidney Dis. 2006 Mar;47(3):478-84.


The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.

Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group.

J Hypertens. 2008 Jul;26(7):1487-96. doi: 10.1097/HJH.0b013e3282ff8864.


Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study.

Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD.

Int J Cardiol. 2008 Sep 26;129(2):187-92. doi: 10.1016/j.ijcard.2008.04.056. Epub 2008 Jul 30.


Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.

Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.

Nephrol Dial Transplant. 2008 Feb;23(2):573-9. Epub 2007 Nov 4.


Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.

Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, Kouz S, Grover J; HOPE Investigators.

Circulation. 2001 Jul 31;104(5):522-6.


The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.

Fox JC, Leight K, Sutradhar SC, Demopoulos LA, Gleim GW, Lewin AJ, Bakris GL.

J Clin Hypertens (Greenwich). 2004 Aug;6(8):437-42; quiz 443-4.


Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.

Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Künzler P, Enseleit F, Périat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F.

Circulation. 2008 Apr 29;117(17):2262-9. doi: 10.1161/CIRCULATIONAHA.107.734384. Epub 2008 Apr 21.


Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.

Arnold JM, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, Lonn E, Pogue J, Bosch J; HOPE Investigators.

Circulation. 2003 Mar 11;107(9):1284-90.


CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.

Spinar J, Vítovec J, Soucek M, Dusek L, Pavlík T; CORD Invesigators.

Vnitr Lek. 2009 May;55(5):481-8.


Supplemental Content

Support Center